2023
A pref-1-controlled non-inflammatory mechanism of insulin resistance
Huang Y, Cui D, Chen L, Tong H, Wu H, Muller G, Qi Y, Wang S, Xu J, Gao X, Fifield K, Wang L, Xia Z, Vanderluit J, Liu S, Leng L, Sun G, McGuire J, Young L, Bucala R, Qi D. A pref-1-controlled non-inflammatory mechanism of insulin resistance. IScience 2023, 26: 106923. PMID: 37283810, PMCID: PMC10239698, DOI: 10.1016/j.isci.2023.106923.Peer-Reviewed Original ResearchInsulin resistanceMIF secretionPref-1 expressionPref-1Fat-induced insulin resistancePlasma MIF levelsNon-inflammatory mechanismsActivation of PAR2Palmitic acid dietHigh fat-induced insulin resistanceWhite adipose tissueSubsequent insulin resistanceMIF levelsPAR2 expressionM2 macrophagesAcid dietAdipose tissueAMPK-dependent mannerEndothelial cellsSecretionIntegrin β1CellsExpressionHigh levelsInflammation
2001
Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo
Hartlapp I, Abe R, Saeed R, Peng T, Voelter W, Bucala R, Metz C. Fibrocytes induce an angiogenic phenotype in cultured endothelial cells and promote angiogenesis in vivo. The FASEB Journal 2001, 15: 2215-2224. PMID: 11641248, DOI: 10.1096/fj.01-0049com.Peer-Reviewed Original ResearchConceptsBlood vessel formationAngiogenic phenotypeVessel formationMesenchymal cell typesEndothelial cell invasionEndothelial cellsExtracellular matrix-degrading enzymesEndothelial cell migrationGrowth factorCellular microenvironmentMatrix-degrading enzymesCell invasionCell migrationCell typesCultured endothelial cellsTube formationHematopoietic growth factorsPromotion of angiogenesisPhenotypeAngiogenesis modelMicrovascular endothelial cellsCultured fibrocytesEnzymeAngiogenesisVivo
1995
Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition
Bucala R, Vlassara H. Advanced Glycosylation Endproducts in Diabetic Renal Disease: Clinical Measurement, Pathophysiological Significance, and Prospects for Pharmacological Inhibition. Blood Purification 1995, 13: 160-170. PMID: 7619388, DOI: 10.1159/000170199.Peer-Reviewed Original ResearchConceptsAdvanced glycosylation endproductsDiabetic renal diseaseNormal renal functionInactivate nitric oxideSpecific therapeutic modalitiesTissue LDL receptorsForms of LDLRenal functionRenal diseaseLDL levelsTherapeutic modalitiesVascular permeabilityPathophysiological significanceAdvanced glycosylationLipoprotein depositionPharmacological inhibitionLDL receptorClinical measurementsNitric oxideEndothelial cellsMarked increaseMiddle moleculesLDLToxic effectsEndproducts
1994
Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease
Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts: Role in diabetic and non‐diabetic vascular disease. Drug Development Research 1994, 32: 77-89. DOI: 10.1002/ddr.430320204.Peer-Reviewed Original ResearchAdvanced glycosylationVascular diseasePhase II clinical trialOxidized low-density lipoproteinSpecific therapeutic modalitiesLow-density lipoproteinDirect toxic effectReversible Schiff base adductsClinical trialsAdvanced glycosylation endproductsTherapeutic modalitiesVascular permeabilityDensity lipoproteinLipoprotein depositionVascular wallELISA techniqueHeterogenous groupPathological effectsEndothelial cellsPharmacological inhibitorsPathological conditionsAgeToxic effectsLipoproteinDisease